Evidence map›Paper›PMID 29076001›Full record

ArticleJournal of neuro-oncology2018

A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker.

Alessandra Santangelo, Pietro Imbrucè, Beatrice Gardenghi, Laura Belli, Rina Agushi, Anna Tamanini, Silvia Munari, Alessandra Maria Bossi, Ilaria Scambi, Donatella Benati and 11 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 9 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 9 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Alessandra SantangeloLaboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy.
Pietro ImbrucèDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Beatrice GardenghiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Laura BelliInstitute of Neurosurgery, University Hospital of Verona, Verona, Italy.
Rina AgushiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Anna TamaniniLaboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy.
Silvia MunariLaboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy.
Alessandra Maria BossiDepartment of Biotechnology, University of Verona, Verona, Italy.
Ilaria ScambiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Donatella BenatiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Raffaella MariottiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Gianfranco Di GennaroLaboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy.
Andrea SbarbatiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Albino EccherDepartment of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
Giuseppe Kenneth RicciardiNeuroradiology Unit, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy.
Elisa Maria CiceriNeuroradiology Unit, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy.
Francesco SalaDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Giampietro PinnaInstitute of Neurosurgery, University Hospital of Verona, Verona, Italy.
Giuseppe LippiLaboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy.
Giulio CabriniLaboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy.
Maria Cristina DechecchiLaboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy. cristina.dechecchi@aovr.veneto.it.ORCID http://orcid.org/0000-0001-7357-2104
University of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant gliomas, the most frequent primary brain tumors, are characterized by a dismal prognosis. Reliable biomarkers complementary to neuroradiology in the differential diagnosis of gliomas and monitoring for post-surgical progression are unmet needs. Altered expression of several microRNAs in tumour tissues from patients with gliomas compared to normal brain tissue have been described, thus supporting the rationale of using microRNA-based biomarkers. Although different circulating microRNAs were proposed in association with gliomas, they have not been introduced into clinical practice so far. Blood samples were collected from patients with high and low grade gliomas, both before and after surgical resection, and the expression of miR-21, miR-222 and miR-124-3p was measured in exosomes isolated from serum. The expression levels of miR-21, miR-222 and miR-124-3p in serum exosomes of patients with high grade gliomas were significantly higher than those of low grade gliomas and healthy controls and were sharply decreased in samples obtained after surgery. The analysis of miR-21, miR-222 and miR-124-3p in serum exosomes of patients affected by gliomas can provide a minimally invasive and innovative tool to help the differential diagnosis of gliomas at their onset in the brain and predict glioma grading and non glial metastases before surgery.

Indexed as

AdultAgedBiomarkers, TumorBrain NeoplasmsDiagnosis, DifferentialExosomesFemaleGliomaHumansMaleMicroRNAsMiddle AgedSensitivity and SpecificityBiomarkers, TumorMicroRNAsMIR222, humanMIRN1243 microRNA, humanMIRN21 microRNA, humanCirculating biomarkersExosomesGliomasMiRNAs

Identifiers

PMID29076001
OpenAlexW2765199261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.